DK1132086T3 - Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt - Google Patents

Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Info

Publication number: DK1132086T3
Authority: DK; Denmark
Prior art keywords: acute; agonists; renal failure; prostaglandin; chronic renal
Prior art date: 2000-01-31

Application number

DK01300690T

Other languages

Danish (da)

English (en)

Inventor

David Duane Thompson

Vishwas Madhav Paralkar

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-31

Filing date

2001-01-25

Publication date

2006-08-28

2001-01-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-08-28 Application granted granted Critical

2006-08-28 Publication of DK1132086T3 publication Critical patent/DK1132086T3/da

Links

239000000556 agonist Substances 0.000 title abstract 3
150000003180 prostaglandins Chemical class 0.000 title abstract 3
208000009304 Acute Kidney Injury Diseases 0.000 title abstract 2
208000033626 Renal failure acute Diseases 0.000 title abstract 2
230000001154 acute effect Effects 0.000 title abstract 2
201000011040 acute kidney failure Diseases 0.000 title abstract 2
208000012998 acute renal failure Diseases 0.000 title abstract 2
208000020832 chronic kidney disease Diseases 0.000 title abstract 2
208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title 1
229960002986 dinoprostone Drugs 0.000 title 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title 1
101150109738 Ptger4 gene Proteins 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK01300690T 2000-01-31 2001-01-25 Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt DK1132086T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US17896800P	2000-01-31	2000-01-31

Publications (1)

Publication Number	Publication Date
DK1132086T3 true DK1132086T3 (da)	2006-08-28

Family

ID=22654657

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01300690T DK1132086T3 (da)	2000-01-31	2001-01-25	Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Country Status (18)

Country	Link
US (1)	US6610719B2 (fr)
EP (1)	EP1132086B1 (fr)
JP (2)	JP3839261B2 (fr)
KR (1)	KR100419684B1 (fr)
AT (1)	ATE327751T1 (fr)
AU (1)	AU774569B2 (fr)
CA (1)	CA2332687A1 (fr)
CO (1)	CO5261529A1 (fr)
CY (1)	CY1105299T1 (fr)
DE (1)	DE60120007T2 (fr)
DK (1)	DK1132086T3 (fr)
ES (1)	ES2263557T3 (fr)
HU (1)	HUP0100495A3 (fr)
IL (1)	IL141120A0 (fr)
NZ (1)	NZ509632A (fr)
PE (1)	PE20011048A1 (fr)
PT (1)	PT1132086E (fr)
ZA (1)	ZA200100827B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001290250A1 (en) *	2000-09-21	2002-04-02	Ono Pharmaceutical Co. Ltd.	Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru)	2000-11-27	2003-08-28	Пфайзер Продактс Инк.	Селективные агонисты рецептора ep4 в лечении остеопороза
PL215425B1 (pl) *	2001-07-16	2013-12-31	Ono Pharmaceutical Co	Pochodna pirolidonu, srodek farmaceutyczny zawierajacy te pochodna i jej zastosowanie
JP4273407B2 (ja) *	2001-07-23	2009-06-03	小野薬品工業株式会社	Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
AU2002340282B2 (en) *	2001-10-23	2007-08-09	Merck Serono Sa	Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US20040254230A1 (en) *	2001-12-03	2004-12-16	Ogidigben Miller J.	Method for treating ocular hypertension
AU2003211574A1 (en)	2002-03-05	2003-09-16	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
EP1490055A1 (fr) *	2002-03-18	2004-12-29	Pfizer Products Inc.	Utilisation d'agonistes du recepteur ep4 selectif pour le traitement de l'insuffisance hepatique, de la perte de la permeabilite du canal arteriel, du glaucome ou de l'hypertension oculaire
US6573294B1 (en) *	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1513589B1 (fr) *	2002-06-06	2010-11-10	Merck Frosst Canada Ltd.	Derives de pyrrolid-2-one 1,5 disubstitues utilises comme agonistes de recepteur ep4 pour traiter des maladies oculaires telles que le glaucome
AU2003237520B2 (en) *	2002-06-10	2009-01-08	Laboratoires Serono Sa	Gamma lactams as prostaglandin agonists and use thereof
HUE029417T2 (en)	2002-10-10	2017-02-28	Ono Pharmaceutical Co	Microspheres containing ONO-1301
FI20030015A0 (fi) *	2003-01-03	2003-01-03	Orion Corp	Menetelmä munuaisten vajaatoiminnan hoitamiseksi
WO2004065365A1 (fr) *	2003-01-21	2004-08-05	Ono Pharmaceutical Co., Ltd.	Derives de 8-azaprostalangine et utilisations de ces derives en tant que medicaments
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
US6734201B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
GB0324269D0 (en) *	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
US20080306155A1 (en) *	2004-09-16	2008-12-11	Roman Richard J	Method for treating renal disease
US7893107B2 (en) *	2005-11-30	2011-02-22	Allergan, Inc.	Therapeutic methods using prostaglandin EP4 agonist components
US20070232660A1 (en) *	2006-04-04	2007-10-04	Allergan, Inc.	Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2094839B1 (fr)	2006-12-08	2020-02-05	University of Rochester	Expansion de cellules souches hématopoïétiques
EP1952823A1 (fr) *	2007-01-30	2008-08-06	AM-Pharma B.V.	Utilisation de phosphatase d'alcaline dans le traitement de la fonction rénale réduite
EP3533445A1 (fr)	2009-03-19	2019-09-04	Fate Therapeutics, Inc.	Compositions comprenant des activateurs d'amp cyclique et/ou des ligands d'ep, et procédés de préparation et utilisation de ceux-ci
CA2738045C (fr)	2010-05-28	2019-02-19	Simon Fraser University	Composes conjugues, leurs procedes de fabrication et leurs utilisations
IN2013CN00342A (fr)	2010-06-17	2015-07-03	Nitto Denko Corp
CN103167876B (zh)	2010-08-12	2016-08-31	菲特治疗公司	改进的造血干细胞和祖细胞疗法
US9682065B2 (en)	2011-08-02	2017-06-20	Ono Pharmaceutical Co., Ltd.	Left ventricular diastolic function improving agent
CA2850484C (fr)	2011-09-30	2021-01-26	Bluebird Bio, Inc.	Composes ameliorant la transduction virale
CN104066837B (zh)	2011-12-02	2020-12-08	菲特治疗公司	增强的干细胞组合物
EP2785350B1 (fr)	2011-12-02	2018-05-02	Fate Therapeutics, Inc.	Méthodes améliorées permettant de traiter l'ischémie
ES2733998T3 (es)	2012-10-29	2019-12-03	Cardio Incorporated	Agente terapéutico específico de enfermedad pulmonar
US10851412B2 (en)	2013-03-15	2020-12-01	Fate Therapeutics, Inc.	Cell potency assay for therapeutic potential
US9943545B2 (en)	2013-03-15	2018-04-17	Fate Therapeutics, Inc.	Stem cell culture media and methods of enhancing cell survival
US9968716B2 (en)	2013-10-15	2018-05-15	Ono Pharmaceutical Co., Ltd.	Drug-eluting stent graft
DK3461891T3 (da)	2014-01-24	2020-08-10	Am-Pharma Bv	Nedstrømsbehandling af en alkalisk phosphatase
WO2015112017A1 (fr)	2014-01-24	2015-07-30	Am-Pharma B.V.	Protéines de type phosphatase alcaline chimère
US9650414B1 (en)	2014-05-30	2017-05-16	Simon Fraser University	Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CA2974903A1 (fr)	2015-01-26	2016-08-04	Fate Therapeutics, Inc.	Cellules a proprietes immuno-regulatrices augmentees et leurs procedes d'utilisation et de fabrication
CN107849072B (zh)	2015-06-12	2020-12-15	西蒙弗雷泽大学	酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
BR112018001232A2 (pt)	2015-07-21	2018-09-25	The Children's Medical Center Corporation	pd-l1 que expressa células-tronco hematopoéticas e usos
CN108883136A (zh)	2016-02-12	2018-11-23	蓝鸟生物公司	Vcn增强子组合物及其使用方法
KR20250134722A (ko)	2016-02-12	2025-09-11	블루버드 바이오, 인코포레이티드.	Vcn 인핸서 조성물 및 이의 사용 방법
EP4538365A3 (fr)	2016-03-04	2025-07-30	The Board Of Trustees Of The Leland Stanford Junior University	Compositions et procédés de régénération musculaire à l'aide de prostaglandine e2
GB2578539B (en)	2017-06-09	2022-08-10	Univ Leland Stanford Junior	Compositions and methods for preventing or treating muscle conditions
WO2019060708A1 (fr)	2017-09-22	2019-03-28	The Children's Medical Center Corporation	Traitement du diabète de type 1 et des maladies ou troubles auto-immuns
JP7853100B2 (ja)	2019-06-05	2026-04-28	オーチャードセラピューティクス（ヨーロッパ）リミテッド	真核細胞を修飾するための組成物及び方法
EP4146797A1 (fr)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Traitement pour les maladies neurodégénératives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4066692A (en)	1972-10-30	1978-01-03	Merck & Co., Inc.	11,12-secoprostaglandins
US3987091A (en)	1973-04-12	1976-10-19	Merck & Co., Inc.	11,12-secoprostaglandins
US4033996A (en)	1973-04-25	1977-07-05	Merck & Co., Inc.	8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (fr)	1973-12-13	1975-06-16	Merck & Co Inc
US3991087A (en)	1973-12-13	1976-11-09	Merck & Co., Inc.	8-Halo-11,12-secoprostaglandins
DK366475A (da)	1974-08-30	1976-03-01	Merck & Co Inc	Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en)	1974-09-13	1976-11-09	Merck & Co., Inc.	16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en)	1974-09-13	1977-10-25	Merck & Co., Inc.	11,12-Seco-prostaglandins
US4177346A (en)	1976-08-06	1979-12-04	Pfizer Inc.	1,5-Disubstituted-2-pyrrolidones
CA1077948A (fr) *	1976-08-06	1980-05-20	Albin J. Nelson	Production de 2-pyrrolidones disubstituees en 1,5
US4175203A (en)	1976-12-17	1979-11-20	Merck & Co., Inc.	Interphenylene 11,12-secoprostaglandins
US4112236A (en)	1977-04-04	1978-09-05	Merck & Co., Inc.	Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US5605814A (en)	1993-08-31	1997-02-25	Merck Frosst Canada Inc.	DNA encoding human prostaglandin receptor EP2
US5716835A (en)	1994-05-05	1998-02-10	Allergan, Inc.	Nucleic acid encoding a novel human EP prostaglandin receptor
US5807895A (en) *	1994-11-29	1998-09-15	Schwarz Pharma, Inc.	Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
UA59384C2 (uk)	1996-12-20	2003-09-15	Пфайзер, Інк.	Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
JPH10265454A (ja)	1997-01-27	1998-10-06	Ono Pharmaceut Co Ltd	３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
WO1998058911A2 (fr)	1997-06-23	1998-12-30	Pfizer Inc.	Agonistes de prostaglandines
SE9702681D0 (sv)	1997-07-10	1997-07-10	Pharmacia & Upjohn Ab	Method and composition for treatment of impotence
US6124314A (en)	1997-10-10	2000-09-26	Pfizer Inc.	Osteoporosis compounds
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TWI249520B (en) *	1998-07-15	2006-02-21	Ono Pharmaceutical Co	5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (fr) *	1998-09-14	2002-09-04	Ono Pharmaceutical Co	DERIVES E DE PHENYL-PROSTAGLANDINE A SUBSTITUTION-$g(V) ET MEDICAMENTS LES CONTENANT COMME INGREDIENT ACTIF
EP1080728A1 (fr) *	1999-03-16	2001-03-07	Toray Industries, Inc.	Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant

2001
- 2001-01-25 AT AT01300690T patent/ATE327751T1/de not_active IP Right Cessation
- 2001-01-25 DE DE60120007T patent/DE60120007T2/de not_active Expired - Fee Related
- 2001-01-25 ES ES01300690T patent/ES2263557T3/es not_active Expired - Lifetime
- 2001-01-25 IL IL14112001A patent/IL141120A0/xx unknown
- 2001-01-25 PT PT01300690T patent/PT1132086E/pt unknown
- 2001-01-25 EP EP01300690A patent/EP1132086B1/fr not_active Expired - Lifetime
- 2001-01-25 DK DK01300690T patent/DK1132086T3/da active
- 2001-01-29 PE PE2001000097A patent/PE20011048A1/es not_active Application Discontinuation
- 2001-01-29 US US09/771,164 patent/US6610719B2/en not_active Expired - Fee Related
- 2001-01-29 CA CA002332687A patent/CA2332687A1/fr not_active Abandoned
- 2001-01-30 AU AU16722/01A patent/AU774569B2/en not_active Ceased
- 2001-01-30 JP JP2001021534A patent/JP3839261B2/ja not_active Expired - Fee Related
- 2001-01-30 HU HU0100495A patent/HUP0100495A3/hu unknown
- 2001-01-30 NZ NZ509632A patent/NZ509632A/xx unknown
- 2001-01-30 ZA ZA200100827A patent/ZA200100827B/xx unknown
- 2001-01-31 KR KR10-2001-0004590A patent/KR100419684B1/ko not_active Expired - Fee Related
- 2001-01-31 CO CO01007013A patent/CO5261529A1/es not_active Application Discontinuation
2006
- 2006-02-24 JP JP2006047746A patent/JP2006182788A/ja active Pending
- 2006-07-04 CY CY20061100920T patent/CY1105299T1/el unknown

Also Published As

Publication number	Publication date
CY1105299T1 (el)	2010-03-03
AU774569B2 (en)	2004-07-01
HUP0100495A3 (en)	2003-12-29
KR100419684B1 (ko)	2004-02-21
US20010041729A1 (en)	2001-11-15
ZA200100827B (en)	2002-07-30
EP1132086A2 (fr)	2001-09-12
ATE327751T1 (de)	2006-06-15
PT1132086E (pt)	2006-09-29
ES2263557T3 (es)	2006-12-16
DE60120007T2 (de)	2006-11-16
KR20010078209A (ko)	2001-08-20
HU0100495D0 (en)	2001-03-28
EP1132086A3 (fr)	2002-01-09
EP1132086B1 (fr)	2006-05-31
US6610719B2 (en)	2003-08-26
AU1672201A (en)	2001-08-02
JP2001233792A (ja)	2001-08-28
CA2332687A1 (fr)	2001-07-31
NZ509632A (en)	2003-01-31
PE20011048A1 (es)	2001-10-19
HUP0100495A2 (en)	2002-10-28
JP2006182788A (ja)	2006-07-13
DE60120007D1 (de)	2006-07-06
IL141120A0 (en)	2002-02-10
JP3839261B2 (ja)	2006-11-01
CO5261529A1 (es)	2003-03-31

Publication	Publication Date	Title
ZA200100827B (en)	2002-07-30	Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure.
PT1305286E (pt)	2005-04-29	Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
DK1339678T3 (da)	2008-02-04	Selektive agonister til EP4-receptor til behandling af osteoporose
DK1202724T3 (da)	2004-01-26	Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
DK1404324T3 (da)	2008-03-31	Prolægemidler af GABA analoger, sammensætninger og anvendelser deraf
EA200601553A1 (ru)	2006-12-29	Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
NL1021454A1 (nl)	2003-03-17	Wassen van CO2 uit methaan bevattende gassen onder toepassing van een waterige stroom.
EA200601552A1 (ru)	2007-02-27	Замещенные конденсированные гетероциклические с-гликозиды
NO20080612L (no)	2008-04-30	Immunokonjugatpreparater
DK1682530T3 (da)	2007-07-16	Pyrrolsubstituerede indoler som inhibitorer af PAI-1
DK1117403T3 (da)	2004-04-13	MGLUR5-antagonister til behandling af smerte og angst
DZ3265A1 (fr)	2000-10-19	Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
EA200601912A1 (ru)	2007-04-27	Применение пептидных соединений для профилактики и лечения хронической головной боли
DK1373220T3 (da)	2007-10-08	Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
DK1448562T3 (da)	2007-09-24	Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
DE60029242D1 (de)	2006-08-17	Arzneien zur begleitenden behandlung von glaukomen
DE60329326D1 (de)	2009-10-29	Tace inhibitoren
BRPI0516128A (pt)	2008-08-26	uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
DK1658062T3 (da)	2010-05-31	Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
DK1301475T3 (da)	2007-04-02	Arylsulfonamider, som serotoninantagonist til behandling af obesitet
DK1642576T3 (da)	2009-04-14	Anvendelse af pyrrolderivater til at bekæmpe angst
DK1177191T3 (da)	2004-04-05	Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
DK1455770T3 (da)	2007-10-08	Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
SE0001373D0 (sv)	2000-04-13	NPY Y1 receptor agonists and antagonists
DK1223930T3 (da)	2006-11-20	Behandling af dyskinesi